Alivexis, Inc.
June 25, 2026
Theater 2
Type: Company Presentation
Focus Area:
AI and Digital Health
Alivexis, Inc. is a technology-driven drug discovery company creating small-molecule therapeutics through advanced molecular simulation and AI. Our proprietary ModBind platform enables high-speed, high-accuracy prediction of absolute protein–ligand binding free energy, supporting rapid hit identification, lead optimization, and candidate selection across diverse targets. By combining ModBind-generated physics-based data with AI and active learning, Alivexis seeks to overcome a key limitation in AI drug discovery: the lack of sufficient high-quality training data. The platform has generated a differentiated portfolio in immunology and oncology, including clinical candidate-stage projects.
Our business focus is partnering with pharma and biotech companies on internal projects and research collaborations for new targets. In 2024, we licensed out one clinical candidate and have initiated multiple pharma collaborations, several of which have concluded successfully.
Company HQ City:
Minato-ku
Company HQ State:
Tokyo
Company HQ Country:
Japan
Year Founded:
2016
Lead Product in Development:
MDI-0151 (cathepsin c inhibitor for neutrophil related diseases), MDI-0238 (WT KIT inhibitor for mast cell related diseases), ALVX-0367 (PARG inhibitor for HRD cancers) and ALVX-0438 (WDR5 inhibitor for myc-high/amp solid and heme cancers)
CEO
S. Roy Kimura
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Three
When you expect your next catalyst update?
Within next 6 months.
What is your next catalyst (value inflection) update?
Establish new collaborations with pharma/biotech companies, license-out internal assets, further development of current pipeline in efficacy and IND-enabling studies including CMC.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}